Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VAL070-A
- Development stage
- Unknown
- Lead developer
- Valbiotis
- Administration
- Oral
01
Overview
VAL070-A is a dietary supplement in capsule form containing a combination of 4 active plant extracts. It has been studied for its effects on lipid profile parameters, including LDL cholesterol, total cholesterol, triglycerides, HDL cholesterol, non-HDL cholesterol, and other metabolic markers. The mechanism of action and the specific plant extracts included are not detailed in public sources, but its primary indication appears to be the modulation of cholesterol and related metabolic parameters in healthy adults, marking it as a multi-ingredient, plant-based product intended for nutritional supplementation rather than pharmaceutical therapy[5].
- Brand names
- VAL070-AVAL-070-AVAL 070-A
- Other names
- VAL070-AVAL-070-AVAL 070-A
Beyond the preview
Go deeper on VAL070-A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VAL070-A.